Scarica l'app Stockscreener
0.3476
2.33%
-0.0083
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3559
Aprire:
$0.36
Volume 24 ore:
4.07M
Relative Volume:
1.58
Capitalizzazione di mercato:
$65.99M
Reddito:
$150.71M
Utile/perdita netta:
$-30.94M
Rapporto P/E:
-1.9672
EPS:
-0.1767
Flusso di cassa netto:
$-20.86M
1 W Prestazione:
+18.15%
1M Prestazione:
+11.09%
6M Prestazione:
-56.51%
1 anno Prestazione:
-73.26%
Intervallo 1D:
$0.34
$0.405
Intervallo di 1 settimana:
$0.28
$0.405
Portata 52W:
$0.261
$1.575
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.3476 | 55.85M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-03 | Downgrade | Needham | Buy → Hold |
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
Form 8K Heron Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Heron Therapeutics signs multi-product license agreement with Long Grove By Investing.com - Investing.com Nigeria
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00 - MarketBeat
Heron Therapeutics, Inc. (HRTX) Options Chain - Yahoo Finance
Heron Therapeutics stock awaits its next reported figures - AD HOC NEWS
Heron Therapeutics (AXD2) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX) - MarketBeat
HRTX - Finviz
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc. - marketbeat.com
Heron Therapeutics stock trades at penny level as biotech focuses on pain and oncology pipeline - ad-hoc-news.de
AXD2 Forecast — Price Target — Prediction for 2027 - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Heron Therapeutics Stock Short Interest Rises to 31.36% - Quiver Quantitative
Heron (HRTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark at the Close; Post-Earnings: The Market Price Advances 2.91% on the DayAnalyst Coverage Count - careplusvn.com
Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron (HRTX) Results Review: EPS Comes in Below Forecast on the Day; Price Reaction: Shares Move 4.13% Down in Latest TradingEarnings Turnaround - vinanet.vn
Heron Therapeutics Earnings Call: Growth Meets New Risks - TipRanks
Heron (HRTX) Watch: Records a 4.65% Increase to $0.31 at the Close; Key Range: the Session Ends Within the Reported Technical Boundaries in the Available RecordIV Contraction - vinanet.vn
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating - Moomoo
Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M - TradingView
HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings - MarketBeat
HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY - webull.com
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating - Moomoo
--HC Wainwright Downgrades Heron Therapeutics to Neutral From Buy - Yahoo Finance
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... - finance.yahoo.com
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates - AlphaStreet
Heron Therapeutics: Q2 Earnings Snapshot - AOL.com
Heron Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Heron Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo Finance
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast By Investing.com - Investing.com Canada
Heron Therapeutics Q2 Earnings Call Highlights - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
development in the article - Minichart
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results - MarketBeat
HERON THERAPEUTICS INC HERON TH (0J4V.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Heron Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook - TradingView
Heron Therapeutics Q2 Revenue Rises To $37.7 Million - Quiver Quantitative
Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling - TradingView
Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell - MarketBeat
HERON THERAPEUTICS Q2 2026 Earnings Preview: Recent $HRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Heron Therapeutics Inc expected to post earnings of 1 cent a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research - MarketBeat
Earnings Preview: HRTX to Report Financial Results Pre-market on August 10 - Moomoo
HRTX Q2'26 Earnings: revenue estimate is 42.19M USD - TradingView
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday - MarketBeat
Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX - TradingView
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):